Strategies for purging cd96+ stem cells in vitro and in vivo new avenues for autologous stem cell transplantation in acute myeloid leukemia

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Staudinger, Matthias ^a   Humpe, Andreas ^a   Gramatzki, Martin ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Acute myeloid leukemia; CD96; Graft engineering; Leukemic stem cells; Purging; Targeted therapy

Indexed keywords

CD123 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD47 ANTIGEN; CD96 ANTIGEN; CELL ANTIGEN; HERMES ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TH111; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CYTOFLUOROMETRY; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LEUKAPHERESIS; LEUKEMIA RELAPSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN ENGINEERING;

EID: 84886943466     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24500     Document Type: Article

References (10)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; PMID:9212098; http://dx.doi.org/10.1038/nm0797-730
2. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101:3142-9; PMID:12468427; http://dx.doi.org/10.1182/blood-2002-10-3062
3. Herr AL, Labopin M, Blaise D, Milpied N, Potter M, Michallet M, et al.; Acute Leukemia Working Party or the European Group for Blood and Marrow Transplantation. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 2007; 21:129-35; PMID:17128198; http://dx.doi. org/10.1038/sj.leu.2404461
4. Brenner MK, Rill DR, Moen RC, Krance RA, Heslop HE, Mirro J Jr., et al. Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci 1994; 716:204-14, discussion 214-5, 225-7; PMID:8024195; http://dx.doi.org/10.1111/j.1749-6632.1994. tb21713.x
5. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007; 19:239-45; PMID:17291742; http://dx.doi.org/10.1016/j. coi.2007.01.005
6. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011; 30:1009-19; PMID:21076471; http://dx.doi.org/10.1038/onc.2010.511
7. Gramatzki M, Ludwig WD, Burger R, Moos P, Rohwer P, Grünert C, et al. Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol 1998; 26:1209-14; PMID:9845376
8. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A 2007; 104:11008-13; PMID:17576927; http://dx.doi.org/10.1073/pnas.0704271104
9. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. Cutting edge: CD96 (tactile) promotes NK celltarget cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 2004; 172:3994-8; PMID:15034010
10. Mohseni Nodehi S, Repp R, Kellner C, Bräutigam J, Staudinger M, Schub N, et al. Enhanced ADCC activity of affinity maturated and Fc-engineered miniantibodies directed against the AML stem cell antigen CD96. PLoS One 2012; 7:e42426; PMID:22879978; http://dx.doi.org/10.1371/journal.pone.0042426